Skip to main content

Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.

TitleMagnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.
Publication TypeJournal Article
Year of Publication2013
AuthorsBickford, C, Magee, LA, Mitton, C, Kruse, M, Synnes, A, Sawchuck, D, Basso, M, Senikas, V, von Dadelszen, P
Corporate AuthorsMAG-CP Working Group
JournalBMC Health Serv Res
Volume13
Pagination527
Date Published2013 Dec 19
ISSN1472-6963
KeywordsCerebral Palsy, Cost Savings, Cost-Benefit Analysis, Decision Trees, Drug Costs, Female, Fetus, Gestational Age, Health Care Costs, Humans, MAG-CP, Magnesium Sulfate, Neuroprotective Agents, Pregnancy, Premature Birth, Prenatal Care, Quality of Life, Quality-Adjusted Life Years, Risk Assessment
Abstract

BACKGROUND: The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at < 32+0 weeks gestation is either imminent or threatened for the purpose of fetal neuroprotection.

METHODS: Multiple decision tree models and probabilistic sensitivity analyses were used to compare the administration of magnesium sulphate with the alternative of no treatment. Two separate cost perspectives were utilized in this series of analyses: a health system and a societal perspective. In addition, two separate measures of effectiveness were utilized: cases of cerebral palsy (CP) averted and quality-adjusted life years (QALYs).

RESULTS: From a health system and a societal perspective, respectively, a savings of $2,242 and $112,602 is obtained for each QALY gained and a savings of $30,942 and $1,554,198 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is imminent. From a health system perspective and a societal perspective, respectively, a cost of $2,083 is incurred and a savings of $108,277 is obtained for each QALY gained and a cost of $28,755 is incurred and a savings of $1,494,500 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is threatened.

CONCLUSIONS: Administration of magnesium sulphate to patients in whom preterm birth is imminent is a dominant (i.e. cost-effective) strategy, no matter what cost perspective or measure of effectiveness is used. Administration of magnesium sulphate to patients in whom preterm birth is threatened is a dominant strategy from a societal perspective and is very likely to be cost-effective from a health system perspective.

DOI10.1186/1472-6963-13-527
Alternate JournalBMC Health Serv Res
Citation Key590
PubMed ID24350635
PubMed Central IDPMC3878233
Grant List / / Canadian Institutes of Health Research / Canada